Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

FDA Breakthrough Therapy Designation

Onco_background

Oncology Today—February 2, 2026

This weekly update in oncology covers regulatory actions, clinical progress,…

Cell_Gene_Therapy

Cell and Gene Therapy Today—January 29, 2026

This week’s Cell and Gene Therapy update highlights significant advancements,…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Lucid Diligence Brief: Universal Health Services acquires Talkspace for $835 million
Lucid Diligence Brief: PRISM BioLab × Receptor.AI collaboration
Public Health Video Recap—March 13, 2026
Respiratory Today—March 13, 2026
Public Health Today—March 13, 2026

Tags

AAV exit abbvie ventures AI in drug discovery Alzheimer’s blood test ANGPTL3 apixaban Arcutis Biktarvy Chiesi CNS therapeutics DB-OTO Diagonal Therapeutics Drug discovery AI Efpeglenatide Eisai Factor Bioscience FcRn inhibitors genome editing GM1 gangliosidosis Hello Heart hepatitis C HER2-positive breast cancer hypotension IAS 2025 IDH1-mutant glioma Ildong oral GLP-1 Infinity influenza innovative designs Ixo-vec gene therapy licensing deals MedMobile modifiable risk factors Neuromuscular disorders PCSK9 inhibitor Pediatric-onset MS Pivekimab Sunirine Qilu Pharmaceutical RNAi RPDD Sonrotoclax Staphylococcus aureus vaccine Tavapadon TB integration UTOpia bioartificial liver

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Lucid Diligence Brief: Universal Health Services acquires Talkspace for $835 million
Lucid Diligence Brief: PRISM BioLab × Receptor.AI collaboration
Public Health Video Recap—March 13, 2026
Respiratory Today—March 13, 2026
Public Health Today—March 13, 2026

TAGS

AAV exit abbvie ventures AI in drug discovery Alzheimer’s blood test ANGPTL3 apixaban Arcutis Biktarvy Chiesi CNS therapeutics DB-OTO Diagonal Therapeutics Drug discovery AI Efpeglenatide Eisai Factor Bioscience FcRn inhibitors genome editing GM1 gangliosidosis Hello Heart hepatitis C HER2-positive breast cancer hypotension IAS 2025 IDH1-mutant glioma Ildong oral GLP-1 Infinity influenza innovative designs Ixo-vec gene therapy licensing deals MedMobile modifiable risk factors Neuromuscular disorders PCSK9 inhibitor Pediatric-onset MS Pivekimab Sunirine Qilu Pharmaceutical RNAi RPDD Sonrotoclax Staphylococcus aureus vaccine Tavapadon TB integration UTOpia bioartificial liver

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy